Antihypertensive treatment for kidney transplant recipients

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2009, Pages

  Cross, Nicholas B ^a   Webster, Angela C ^b   Masson, Philip ^c   O'Connell, Philip J ^d   Craig, Jonathan C ^d  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CYCLOSPORIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FELODIPINE; FOSINOPRIL; GALLOPAMIL; ISRADIPINE; LACIDIPINE; LISINOPRIL; LOSARTAN; NIFEDIPINE; NITRENDIPINE; PERINDOPRIL; PLACEBO; TACROLIMUS; TERTATOLOL; THEOPHYLLINE; UNINDEXED DRUG; VERAPAMIL;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MEASUREMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CREATININE CLEARANCE; GLOMERULUS FILTRATION RATE; HEART HEMODYNAMICS; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; PROGNOSIS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 68249119552     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003598.pub2     Document Type: Review

References (291)

1. * Alcaraz A, Oppenheimer F, Talbot-Wright R, Fernandez-Cruz L, Manalich M, Garcia-Pages E, et al.Effect of diltiazem in the prevention of acute tubular necrosis, acute rejection, and cyclosporine levels. Transplantation Proceedings 1991;23(5):2383-2384 [MEDLINE: 1926395]
2. Oppenheimer F, Alcaraz A, Manalich M, Ricart MJ, Vilardell J, Campistol JM, et al.Influence of the calcium blocker diltiazem on the prevention of acute renal failure after renal transplantation. Transplantation Proceedings 1992;24(1):50-51 [MEDLINE: 1539339]
3. * Altiparmak MR, Trablus S, Apaydin S, Basar O, Sariyar M, Serdengecti K, et al.Is losartan as effective as enalapril on posttransplant persistent proteinuria?. Transplantation Proceedings 2001;33(7-8):3368-3369 [MEDLINE: 11750440]
4. * Andres A, Morales E,Morales JM, Bosch I, Campo C, Ruilope LM, Valsartan in Renal Transplantation Group. Efficacy and safety of valsartan, an angiotensin II receptor antagonist, in hypertension after renal transplantation: a randomized multicenter study. Transplantation Proceedings 2006;38(8):2419-2423 [MEDLINE: 17097955]
5. Jardine AG, Mann JF, Oddou P, Mann J, Pedersen T, Ruilope LM. Valsartan is effective in patients with post-transplant hypertension [abstract]. Journal of the American Society of Nephrology 2000;11(Sept):692A. [CENTRAL: CN-00583214]
6. * Barenbrock M, Kosch M, Kobelt V, Hohage H, Rahn KH, Hausberg M. A randomised trial of effects of AT1-rezeptor- vs. calcium-channel-blockade on arterial function in hypertensive renal transplant recipients [abstract]. Deutsche Medizinische Wochenschrift 2001;126:S193. [CENTRAL: CN-00382259]
7. Kosch M, Barenbrock M, Kobelt V, Hohage H, Rahn KH, Hausberg M. Studies of effects of antihypertensive treatment by AT1-receptorvs. calcium-channel- blockade on sympathetic nerve activity in renal transplant recipients [abstract]. Deutsche Medizinische Wochenschrift 2001;126(Suppl 3):S196. [CENTRAL: CN-00449923]
8. * Barri YM, Ramos EL, Orig J, Karlix J, Peterson JC, Parris CJ. Isradipine (ISR) in the treatment of hypertension in renal transplant patients (RTP) on cyclosporin (CSA): a randomized open-label cross-over study [abstract]. Journal of the American Society of Nephrology 1995;6(3):1072. [CENTRAL: CN-00483144]
9. Beckingham IJ, Hinwood M, Woodrow G, Burden RP. Use of ACE inhibitors to control transplant erythrocytosis [abstract]. Nephrology Dialysis Transplantation 1993;8(9):1035. [CENTRAL: CN-00583801]
10. * Beckingham IJ, Woodrow G, Hinwood M, Rigg KM, Morgan AG, Burden RP, et al.A randomized placebo-controlled study of enalapril in the treatment of erythrocytosis after renal transplantation. Nephrology Dialysis Transplantation 1995;10(12):2316-2320 [MEDLINE: 8808232]
11. Woodrow G, Beckingham IJ, Hinwood M, Broughton-Pipkin F. A randomized placebo-controlled study of enalapril in post-transplant erythrocytosis [abstract]. Nephrology Dialysis Transplantation 1995;10(5):730. [CENTRAL: CN-00448419] (Pubitemid 26033450)
12. * Campistol JM, Oppenheimer F, Vilardell J, Ricart MJ, Alcaraz A, Ponz E, et al.Interaction between ciclosporin and diltiazem in renal transplant patients. Nephron 1991;57(2):241-242 [MEDLINE: 2020357]
13. Castelao AM, Hueso M, Sanz V, Rejas J, Sarrias X, Alsina J, et al.Double blind, crossover, comparative study of doxazosin vs enalapril in the treatment of hypertension in renal transplantation under cyclosporin immunosuppression [abstract]. Journal of the American Society of Nephrology 2001;12(Program & Abstracts):881A. [MEDLINE: CN-00550748]
14. * Martinez-Castelao A, Hueso M, Sanz V, Rejas J, Sarrias J, Alsina J, et al.Double-blind, crossover, comparative study of doxazosin and enalapril in the treatment of hypertension in renal transplant patients under cyclosporine immunosuppression. Transplantation Proceedings 2002;34(1):403-406 [MEDLINE: 11959345]
15. * Celik A, Ok E, Unsal A, Toz H, Atabay G. Comparison of enalapril and losartan in the treatment of posttransplant erythrocytosis. Nephron 2000;86(3):394-395 [MEDLINE: 11096321]
16. Celik A, Unsal A, Duman S, Ok E, Ozkahya M, Uslu A, et al.Enalapril and losartan on the treatment of posttransplantation erythrocytosis [abstract]. Nephrology Dialysis Transplantation 1999;14(9):A292. [CENTRAL: CN-00483807]
17. Chanard J, Toupance O, Lavaud S, de Ligny BH, Moulin B. Amlodipine reduces cyclosporine-induced hyperuricemia in hypertensive renal transplant recipients [abstract]. Journal of the American Society of Nephrology 2001;12(Program & Abstracts):882A. [CENTRAL: CN-00550395]
18. * Chanard J, Toupance O, Lavaud S, Hurault D, Bernaud C, Moulin B. Amlodipine reduces cyclosporin-induced hyperuricaemia in hypertensive renal transplant recipients. Nephrology Dialysis Transplantation 2003;18(10):2147-2153 [MEDLINE: 13679494]
19. * Chrysostomou A, Walker RG, Russ GR, d'Apice AJ, Kincaid-Smith P, Mathew TH. Diltiazem in renal allograft recipients receiving cyclosporine. Transplantation 1993;55(2):300-304 [MEDLINE: 8434380]
20. Kelly JJ, Walker RG, d'Apice AJ, Kincaid-Smith P. A prospective study of the effect of diltiazem in renal allograft recipients receiving cyclosporine A: preliminary results. Transplantation Proceedings 1990;22(5):2127-2128 [MEDLINE: 2219318]
21. Dawidson I, Rooth P, Alway C, Dulzo T, Palmer B, Lu C, et al.Verapamil prevents posttransplant delayed function and cyclosporine A nephrotoxicity. Transplantation Proceedings 1990;22(4):1379-1380 [MEDLINE: 2202113] (Pubitemid 20284359)
22. * Dawidson I, Rooth P, Lu C, Sagalowsky A, Diller K, Palmer B, et al.Verapamil improves the outcome after cadaver renal transplantation. Journal of the American Society of Nephrology 1991;2(5):983-990 [MEDLINE: 1760541]
23. El Agroudy A, Hassan N, El Sawy E, Mostafa A, Moussa O, Sobh M, et al.Losartan could prevent progression of chronic allograft nephropathy: a prospective randomized study [abstract]. Nephrology Dialysis Transplantation 2003;18(Suppl 4):500. [CENTRAL: CN-00445210]
24. * El Agroudy AE, Hassan NA, Foda MA, Ismail AM, el Sawy EA, Mousa O, et al.Effect of angiotensin II receptor blocker on plasma levels of TGF-beta 1 and interstitial fibrosis in hypertensive kidney transplant patients. American Journal of Nephrology 2003;23(5):300-306 [MEDLINE: 12904684]
25. El Agroudy A, Hassan N, El Sawy E, Mostafa A, Moussa O, Sobh M, et al.Losartan could prevent progression of chronic allograft nephropathy: a prospective randomized study [abstract]. Nephrology Dialysis Transplantation 2003;18(Suppl 4):500. [CENTRAL: CN-00445210]
26. * El Agroudy AE, Hassan NA, Foda MA, Ismail AM, el Sawy EA, Mousa O, et al.Effect of angiotensin II receptor blocker on plasma levels of TGF-beta 1 and interstitial fibrosis in hypertensive kidney transplant patients. American Journal of Nephrology 2003;23(5):300-306 [MEDLINE: 12904684]
27. Formica RN, Friedman AL, Lorber MI, Bia MJ. A randomized controlled trial comparing losartan to amlodipine as initial therapy for hypertension in the immediate post transplant period [abstract]. American Journal of Transplantation 2005;5(Suppl 11):200.
28. * Formica RN, Friedman AL, Lorber MI, Smith JD, Eisen T, Bia MJ. A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period. Nephrology Dialysis Transplantation 2006;21(5):1389-1394 [MEDLINE: 16431893]
29. * Frei U, Harms A, Bakovic-Alt R, Pichlmayr R, Koch KM. Calcium channel blockers for kidney protection. Journal of Cardiovascular Pharmacology 1990;16 Suppl 6:S11-S15. [MEDLINE: 1707109]
30. Frei U, Margreiter R, Harms A, Bosmuller C, Neumann KH, Viebahn R, et al.Preoperative graft reperfusion with a calcium antagonist improves initial function: preliminary results of a prospective randomized trial in 110 kidney recipients. Transplantation Proceedings 1987;19(5):3539-3541 [MEDLINE: 3313853] (Pubitemid 18023705)
31. * Gossmann J, Mondorf U, Dietz A, Kramer W, Kachel HG, Geiger H, et al.A randomized prospective double-blind placebo-controlled study of gallopamil, calcium antagonist of the verapamil type, in stable cyclosporine-treated renal transplant recipients. Transplantation Proceedings 2002;34(5):1767-1770 [MEDLINE: 12176568]
32. Scheuermann EH, Gossmann J, Peschke B, Kachel HG, Schoeppe W. A randomized, double blind, placebo controlled study of gallo-pamil in cyclosporine treated renal transplant recipients [abstract]. Journal of the American Society of Nephrology 1995;6(3):1114. [CENTRAL: CN-00485739]
33. * Gronhagen-Riska C, Fyhrquist F, Ahonen J, von Willebrand E, Hayry P. Angiotensin I-converting enzyme inhibition after renal transplantation. Scandinavian Journal of Urology & Nephrology Supplementum 1984;79:63-67 [MEDLINE: 6089320]
34. * Guerin C, Berthoux P, Broyet C, Berthoux F. Effects of diltiazem on arterial pressure and renal function in renal transplanted and cyclosporin A treated subjects. Results after 3 months of a prospective study. Archives des Maladies du Coeur et des Vaisseaux 1989;82(7):1223-1227 [MEDLINE: 2510652]
35. * Halimi JM, Giraudeau B, Buchler M, Al Najjar A, Etienne I, Laouad I, et al.Enalapril/amlodipine combination in cyclosporine-treated renal transplant recipients: a prospective randomized trial. Clinical Transplantation 2007;21(2):277-284 [MEDLINE: 17425758]
36. Donnelly P. Effect of nifedipine on immediate graft function on cyclosporin-treated renal transplant patients: a prospective randomized study. British Journal of Surgery 1992;79(5):445. [MEDLINE: CN-00583384]
37. Donnelly PK, Feehally J, Jurewicz A, Furness P, McCullough T, Harper SJ, et al.Renal transplantation: nifedipine for the nonstarters? A prospective randomised study. Transplantation Proceedings 1993;25(1 Pt 1):600-601 [MEDLINE: 8438431] (Pubitemid 23082490)
38. Harper SJ, Abrams K, Harris K, Jurewicz A, Walls J, Veitch P, et al.Beneficial effects of oral nifedipine on cyclos(CsA)-treated renal transplant recipients [abstract]. Nephrology Dialysis Transplantation 1995;10(12):2387. [CENTRAL: CN-00261157]
39. Harper SJ, Harris K, Jurewicz A, Walls J, Veitch P, Feehally J. Beneficial effects of oral nifedipine on cyclosporin (cya) treated renal allograft recipients - a randomised prospective study [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid (Spain). 1995:381. [CENTRAL: CN-00509226]
40. * Harper SJ, Moorhouse J, Abrams K, Jurewicz A, Nicholson M, Horsburgh T, et al.The beneficial effects of oral nifedipine on cyclosporin-treated renal transplant recipients - a randomised prospective study. Transplant International 1996;9(2):115-125 [MEDLINE: 8639252]
41. Harper SJ, Moorhouse J, Veitch PS, Bell PR, Horsburgh T, Walls J, et al.Improved immediate graft function with nifedipine in cyclosporine-treated renal allograft recipients - a randomized prospective study. Transplantation 1992;54(4):742-743 [MEDLINE: 1412770]
42. Harper SJ, Moorhouse J, Veitch PS, Horsburgh T, Bell PR, Donnelly PK, et al.Nifedipine improves immediate, and 6- and 12-month graft function in cyclosporin A (CyA) treated renal allograft recipients. Transplant International 1992;5 Suppl 1:S69-72. [MEDLINE: 14621737]
43. Harper SJ, Moorhouse J, Walls J, Veitch PS, Bell PR, Donnelly PK, et al.Protective effects of nifedipine in immediate and 6-month graft function in cyclosporin A treated renal allograft recipients [abstract]. Nephrology Dialysis Transplantation 1991;6(11):904. [CENTRAL: CN-00260679]
44. McCulloch TA, Harper SJ, Donnelly PK, Moorhouse J, Bell PR, Walls J, et al.Influence of nifedipine on interstitial fibrosis in renal transplant allografts treated with cyclosporin A. Journal of Clinical Pathology 1994;47(9):839-842 [MEDLINE: 7962654]
45. Morgan JDT, Swarbrick MJ, Edwards CM, Donnelly PK. Cyclosporin, nifedipine and gingival hyperplasia: a randomized controlled study. Transplant International 1994;7 Suppl 1:S320-1. [MEDLINE: 11271240]
46. Hausberg M, Barenbrock M, Hohage H, Heidenreich S, Rahn KH. Efficacy and safety of the ace-inhibitor quinapril as compared to the beta-blocker atenolol in hypertensive renal allograft recipients [abstract]. 35th Congress European Renal Association. European Dialysis and Transplantation Association; 1998 Jun 6-9; Rimini (Italy). 1998:359. [CENTRAL: CN-00484273]
47. * Hausberg M, Barenbrock M, Hohage H, Muller S, Heidenreich S, Rahn KH. ACE inhibitor versus beta-blocker for the treatment of hypertension in renal allograft recipients. Hypertension 1999;33(3):862-868 [MEDLINE: 10082500]
48. Suwelack B, Gerhardt U, Hausberg M, Rahn KH, Hohage H. Comparison of quinapril versus atenolol: effects on blood pressure and cardiac mass after renal transplantation. American Journal of Cardiology 2000;86(5):583-585 [MEDLINE: 11009288] (Pubitemid 30674324)
49. Suwelack B, Kempkes-Koch M, Kobelt V, Hillebrand U, Matzkies F, Gerhardt U, et al.Impact of ACE polymorphism on renal allograft function, blood pressure, and proteinuria under ACE inhibition. Transplantation Proceedings 2002;34(5):1763-1766 [MEDLINE: 12176567] (Pubitemid 34895314)
50. Suwelack B, Kobelt V, Erfmann M, Hausberg M, Gerhardt U, Rahn KH, et al.Long-term follow-up of ACE-inhibitor versus beta-blocker treatment and their effects on blood pressure and kidney function in renal transplant recipients. Transplant International 2003;16(5):313-320 [MEDLINE: 12759722] (Pubitemid 36733742)
51. Suwelack B, Witta J, Hausberg M, Barenbrock M, Rahn KH. Arterial vessel wall hypertrophy in renal transplant recipients: effects of ace inhibitor and b - blocker treatment [abstract]. 35th Congress. European Renal Association. European Dialysis and Transplantation Association; 1998 Jun 6-9; Rimini (Italy). 1998:195. [CENTRAL: CN-00486079]
52. Hernandez E, Morales JM. Effect of captopril on post-transplant erythrocytosis: a controlled study [abstract]. Nephrology Dialysis Transplantation 1993;8(9):1041. [CENTRAL: CN-00260892]
53. * Hernandez E, Morales JM, Andres A, Ortuno B, Praga M, Alcazar JM, et al.Usefulness and safety of treatment with captopril in posttransplant erythrocytosis. Transplantation Proceedings 1995;27(4):2239-2241 [MEDLINE: 7652789]
54. Hernandez E, Morales JM, Andres A, Ortuno B, Praga M, Alcazar JM, et al.Usefulness of treatment with captopril on post-transplant erythrocytosis (PTE). A controlled study [abstract]. Journal of the American Society of Nephrology 1993;4(Program & Abstracts):940. [CENTRAL: CN-00484334]
55. Hernandez D, Lacalzada J, Linares J, Barragan A, Higueras L, Lorenzo V, et al.Regression of left ventricular hypertrophy (LVH) by lisinopril after renal transplantation (RT). Role of angiotensin-converting-enzyme (ACE) gene polymorphism [abstract]. Journal of the American Society of Nephrology 1998;9(Program & Abstracts):708A. [CENTRAL: CN-00445703]
56. Hernandez D, Lacalzada J, Linares J, Rodriguez A, Laynez I, Higueras L, et al.Regression of left ventricular hypertrophy (LVH) by an angiotensin-converting-enzyme inhibitor (ACEI) after renal transplantation (RT) [abstract]. Journal of the American Society of Nephrology 1997;8(Program & Abstracts):714A. [CENTRAL: CN-00445704]
57. * Hernandez D, Lacalzada J, Salido E, Linares J, Barragan A, Lorenzo V, et al.Regression of left ventricular hypertrophy by lisinopril after renal transplantation: role of ACE gene polymorphism. Kidney International 2000;58(2):889-897 [MEDLINE: 10916115]
58. Inigo P, Campistol JM, Lario S, Bescos M, Oppenheimer F. Losartan normalizes the plasma levels of TGF-β1 in a random, crossover study (losartan vs. amlodipine) in renal transplant patients treated with CsA [abstract]. XVIII International Congress of the Transplantation Society; 2000 Aug 27-Sep 1; Rome (Italy). 2000. [CENTRAL: CN-00671770]
59. * Inigo P, Campistol JM, Lario S, Piera C, Campos B, Bescos M, et al.Effects of losartan and amlodipine on intrarenal hemodynamics and TGF-beta(1) plasma levels in a crossover trial in renal transplant recipients. Journal of the American Society of Nephrology 2001;12(4):822-827 [MEDLINE: 11274244]
60. Inigo P, Campistol JM, Piera C, Oppenheimer F. Effects on renal hemodynamics of losartan vs. amlodipine in a cross-over trial in renal transplant patients [abstract]. XVIII International Congress of the Transplantation Society; 2000 Aug 27-Sep 1; Rome (Italy). 2000. [CENTRAL: CN-00445853]
61. Inigo PJ, Campistol JM, Lario S, Bescos M, Oppenheimer F. Losartan normalizes the plasma levels of tgf-b1 in a random, crossover study (losartan vs amlodipine) in renal transplant patients treated with cyclosporine[abstract]. Journal of the American Society of Nephrology 1999;10(Program & Abstracts):759A.
62. * Kim IG, Bagdasaryan AR, Birukova LS, Iljinsky IM, Tomilina NA. The effect of enalapril on the progression of chronic allograft nephropathy. [abstract]. Nephrology Dialysis Transplantation 2002;17(Suppl 1):324. [CENTRAL: CN-00644137]
63. * Kumana CR, Tong MK, Li CS, Lauder IJ, Lee JS, Kou M, et al.Diltiazem co-treatment in renal transplant patients receiving microemulsion cyclosporin. British Journal of Clinical Pharmacology 2003;56(6):670-678 [MEDLINE: 14616428]
64. Kuypers DR, Neumayer HH, Fritsche L, Budde K, Banrenterghem Y. Calciumchannel blockade and preservation of renal allograft function in cyclosporine-treated recipients: a multicentre, prospective randomized, placebo-controlled, 2-year study. [abstract]. Journal of the American Society of Nephrology 2004;15(Oct):526A. [CENTRAL: CN-00644135]
65. * Kuypers DR, Neumayer HH, Fritsche L, Budde K, Rodicio JL, Vanrenterghem Y, et al.Calcium channel blockade and preservation of renal graft function in cyclosporine-treated recipients: a prospective randomized placebo-controlled 2-year study. Transplantation 2004;78(8):1204-1211 [MEDLINE: 15502721]
66. Kuypers DRJ, Neumayer HH, Fritsche L, Budde K, Vanrenterghem Y. Calcium channel blockade and prevention of renal graft function deterioration in cyclosporine-treated recipients: a multi-centre prospective, randomized, placebo-controlled, 2-year study. [abstract]. American Journal of Transplantation 2004;4(Suppl 8):432. [CENTRAL: CN-00509299] (Pubitemid 39426441)
67. * Ladefoged SD, Pedersen E, Hammer M, Rasmussen KC, Hansen FM, Andersen CB. Influence of diltiazem on renal function and rejection in renal allograft recipients receiving triple-drug immunosuppression: a randomized, double-blind, placebo-controlled study. Nephrology Dialysis Transplantation 1994;9(5):543-547 [MEDLINE: 8090335]
68. * Lehtonen S, Isoniemi H, Salmela K. A randomised placebo controlled study on initial isradipine therapy in renal transplantation: long-term results [abstract]. Nephrology Dialysis Transplantation 2000;15(9):A276. [CENTRAL: CN-00461150]
69. Madsen JK, Kornerup HJ, Sorensen SS, Zachariae H, Pedersen EB. Ciclosporine nephrotoxicity can be counteracted by a calcium antagonist (felodipine) in acute and short-term studies [abstract]. Journal of the American Society of Nephrology 1995;6(3):1102. [CENTRAL: CN-00485392]
70. * Madsen JK, Sorensen SS, Hansen HE, Pedersen EB. The effect of felodipine on renal function and blood pressure in cyclosporin-treated renal transplant recipients during the first three months after transplantation. Nephrology Dialysis Transplantation 1998;13(9):2327-2334 [MEDLINE: 9761517]
71. Madsen JK, Sorensen SS, Zachariae H, Pedersen EB. Improvement in renal function by felodipine during cyclosporine treatment in acute and short-term studies. Kidney International - Supplement 1996;49:S94-6. [MEDLINE: 8743522] (Pubitemid 26000758)
72. Aasebo W, Midtvedt K, Hartmann A, Stavem K. Predictors of health-related quality of life in hypertensive recipients following renal transplantation. Clinical Transplantation 2005;19(6):756-762 [MEDLINE: 16313321] (Pubitemid 41748728)
73. Asberg A, Midtvedt K, Vassbotn T, Hartmann A. Better microvascular function on long-termtreatment with lisinopril than with nifedipine in renal transplant recipients. Nephrology Dialysis Transplantation 2001;16(7):1465-1470 [MEDLINE: 11427642] (Pubitemid 32640605)
74. Midtvedt K, Hartmann A, Foss A, Fauchald P, Nordal KP, Rootwelt K, et al.Improved long-term graft function and fewer rejection episodes in hypertensive renal transplant patients treated with nifedipine as compared to lisinopril. Journal of the American Society of Nephrology 1999;10(Program & Abstracts):737A. [CENTRAL: CN-00626112]
75. * Midtvedt K, Hartmann A, Foss A, Fauchald P, Nordal KP, Rootwelt K, et al.Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared to lisinopril. Transplantation 2001;72(11):1787-1792 [MEDLINE: 11740389]
76. Midtvedt K, Hartmann A, Holdaas H, Fauchald P. Efficacy of nifedipine or lisinopril in the treatment of hypertension after renal transplantation: a double-blind randomised comparative trial. Clinical Transplantation 2001;15(6):426-431 [MEDLINE: 11737121] (Pubitemid 33094995)
77. Midtvedt K, Hartmann A, Holdaas H, Ihlen H, Fauchald P. Reduction of left ventricular mass by lisinopril and nifedipine in hypertensive renal transplant recipients: a 2 year prospective randomized double-blind single centre study [abstract]. Journal of the American Society of Nephrology 2001;12(Program & Abstracts):907A. [CENTRAL: CN-00626111]
78. Midtvedt K, Hatmann A, Fauchald P, Sund S, Foss A, Nordal KP, et al.Nifedipine slow release reduces the incidence of acute rejections in hypertensive renal transplant recipients [abstract]. Nephrology Dialysis Transplantation 1999;14(9):A308. [CENTRAL: CN-00485098]
79. Midtvedt K, Ihlen H, Hartmann A, Bryde P, Bjerkely BL, Foss A, et al.Reduction of left ventricular mass by lisinopril and nifedipine in hypertensive renal transplant recipients: a prospective randomized double-blind study. Transplantation 2001;72(1):107-111 [MEDLINE: 11468543] (Pubitemid 32652514)
80. Morales JM, Andres A, Alvarez C, Prieto C, Ortuno B, Ortuno T, et al.Calcium channel blockers and early cyclosporine nephrotoxicity after renal transplantation: a prospective randomized study. Transplantation Proceedings 1990;22(4):1733-1735 [MEDLINE: 2389446] (Pubitemid 20284512)
81. * Morales JM, Andres A, Prieto C, Ortuno B, Estenoz J, Dorado C, et al.Calcium antagonist treatment of recipients minimizes early cyclosporine nephrotoxicity in renal transplantation: a prospective randomized trial. Transplantation Proceedings 1989;21(1 Pt 2):1537-1539 [MEDLINE: 2652496]
82. Morales JM, Andres A. Calcium antagonist therapy prevents chronic cyclosporin nephrotoxicity after renal transplantation: A prospective study [abstract]. Nephrology Dialysis Transplantation 1991;6:832. [CENTRAL: CN-00260661]
83. Morales JM, Andres A, Hernandez E, Praga M, Ruilope LM, Rodicio JL. Long-term protective effect of calcium antagonist (CA) on renal function in hypertensive renal transplant (RT) patients on ciclosporine (CyA) therapy. a five-year prospective randomized study [abstract]. Journal of the American Society of Nephrology 1993;4 (Program & Abstracts):950. [CENTRAL: CN-00487735]
84. Morales JM, Andres A, Rodicio JL. Beneficial effects of calcium antagonists on cyclosporin nephrotoxicity after clinical renal transplantation. Nephrology Dialysis Transplantation 1993;8(9):880. [MEDLINE: 8255527] (Pubitemid 23287004)
85. Morales JM, Andres A, Rodriguez PE, Alcazar JM, Montoyo C, Rodicio JL. Calcium antagonist therapy prevents chronic cyclosporine nephrotoxicity after renal transplantation: a prospective study. Transplantation Proceedings 1992;24(1):89-91. [MEDLINE: 1347185]
86. * Morales JM, Rodriguez-Paternina E, Araque A, Andres A, Hernandez E, Ruilope LM, et al.Long-term protective effect of a calcium antagonist on renal function in hypertensive renal transplant patients on cyclosporine therapy: a 5-year prospective randomized study. Transplantation Proceedings 1994;26(5):2598-2599 [MEDLINE: 7940807]
87. * Mourad G, Ribstein J, Mimran A. Converting-enzyme inhibitor versus calcium antagonist in cyclosporine-treated renal transplants. Kidney International 1993;43(2):419-425 [MEDLINE: 8382753]
88. Ok E, Akcicek F.Comparison of enalapril and theophylline treatment for posttransplant erythrocytosis (PTE) [abstract]. Nephrology Dialysis Transplantation 1995;10(6):1070. [CENTRAL: CN-00261155]
89. * Ok E, Akcicek F, Toz H, Kurat S, Tobu M, Baci A, et al.Comparison of the effects of enalapril and theophylline on polycythemia after renal transplantation. Transplantation 1995;59(11):1623-1626 [MEDLINE: 7778179]
90. * Paoletti E, Cassottana P, Amidone M, Gherzi M, Rolla D, Cannella G. ACE inhibitors and persistent left ventricular hypertrophy after renal transplantation: a randomized clinical trial. American Journal of Kidney Diseases 2007;50(1):133-142 [MEDLINE: 17591533]
91. * Patton PR, Brunson ME, Pfaff WW, Howard RJ, Peterson JC, Ramos EL, et al.A preliminary report of diltiazem and ketoconazole. Their cyclosporine-sparing effect and impact on transplant outcome. Transplantation 1994;57(6):889-892 [MEDLINE: 8154037]
92. * Pirsch JD, D'Alessandro AM, Roecker EB, Knechtle SJ, Reed A, Sollinger HW, et al.A controlled, double-blind, randomized trial of verapamil and cyclosporine in cadaver renal transplant patients. American Journal of Kidney Diseases 1993;21(2):189-195 [MEDLINE: 8430681]
93. Barenbrock M, Breuer J, Schroder K, Wagner K, Neumayer HH, Rahn KH. A study of the nephroprotective effect of nitrendipine after renal transplantation [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid (Spain). 1995:387. [CENTRAL: CN-00602140]
94. Barenbrock M, Colmorgen U, Firschka E, Gellert J, Lippert J, Schroder K, et al.A multicenter, randomized, double-blind, placebo-controlled, two-year trial to study the effect of nitrendipine on chronic renal transplant function. Clinical Nephrology 1995;43(6):388-391 [MEDLINE: 7554523]
95. Barenbrock M, Klan R. Effect of nitrendipine on kidney function after renal transplantation [abstract]. Nephrology Dialysis Transplantation 1996;11(7):1466. [CENTRAL: CN-00261173]
96. * Rahn KH, Barenbrock M, Fritschka E, Heinecke A, Lippert J, Schroeder K, et al.Effect of nitrendipine on renal function in renal-transplant patients treated with cyclosporin: a randomised trial. Lancet 1999;354(9188):1415-1420 [MEDLINE: 10543667]
97. Rockstroh JK, Schobel HP, Vogt-Ladner G, Hauser I, Neumayer HH, Schmieder RE. Blood pressure independent effects of nitrendipine on cardiac structure in patients after renal transplantation. Nephrology Dialysis Transplantation 1997;12(7):1441-1447 [MEDLINE: 9249783] (Pubitemid 27353037)
98. Barenbrock M, Breuer J, Schroder K, Wagner K, Neumayer HH, Rahn KH. A study of the nephroprotective effect of nitrendipine after renal transplantation [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid (Spain). 1995:387. [CENTRAL: CN-00602140]
99. Barenbrock M, Colmorgen U, Firschka E, Gellert J, Lippert J, Schroder K, et al.A multicenter, randomized, double-blind, placebo-controlled, two-year trial to study the effect of nitrendipine on chronic renal transplant function. Clinical Nephrology 1995;43(6):388-391 [MEDLINE: 7554523]
100. Barenbrock M, Klan R. Effect of nitrendipine on kidney function after renal transplantation [abstract]. Nephrology Dialysis Transplantation 1996;11(7):1466. [CENTRAL: CN-00261173]
101. * Rahn KH, Barenbrock M, Fritschka E, Heinecke A, Lippert J, Schroeder K, et al.Effect of nitrendipine on renal function in renal-transplant patients treated with cyclosporin: a randomised trial. Lancet 1999;354(9188):1415-1420 [MEDLINE: 10543667]
102. Rockstroh JK, Schobel HP, Vogt-Ladner G, Hauser I, Neumayer HH, Schmieder RE. Blood pressure independent effects of nitrendipine on cardiac structure in patients after renal transplantation. Nephrology Dialysis Transplantation 1997;12(7):1441-1447 [MEDLINE: 9249783] (Pubitemid 27353037)
103. Barenbrock M, Breuer J, Schroder K, Wagner K, Neumayer HH, Rahn KH. A study of the nephroprotective effect of nitrendipine after renal transplantation [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid (Spain). 1995:387. [CENTRAL: CN-00602140]
104. Barenbrock M, Colmorgen U, Firschka E, Gellert J, Lippert J, Schroder K, et al.A multicenter, randomized, double-blind, placebo-controlled, two-year trial to study the effect of nitrendipine on chronic renal transplant function. Clinical Nephrology 1995;43(6):388-391 [MEDLINE: 7554523]
105. Barenbrock M, Klan R. Effect of nitrendipine on kidney function after renal transplantation [abstract]. Nephrology Dialysis Transplantation 1996;11(7):1466. [CENTRAL: CN-00261173]
106. * Rahn KH, Barenbrock M, Fritschka E, Heinecke A, Lippert J, Schroeder K, et al.Effect of nitrendipine on renal function in renal-transplant patients treated with cyclosporin: a randomised trial. Lancet 1999;354(9188):1415-1420 [MEDLINE: 10543667]
107. Rockstroh JK, Schobel HP, Vogt-Ladner G, Hauser I, Neumayer HH, Schmieder RE. Blood pressure independent effects of nitrendipine on cardiac structure in patients after renal transplantation. Nephrology Dialysis Transplantation 1997;12(7):1441-1447 [MEDLINE: 9249783] (Pubitemid 27353037)
108. Argani H, Ghorbanihaghjo A, Aghaeishahsavari M, Noroozianavval M, Rashtchizadeh N, Veisi P, et al.Effects of losartan and enalapril on high-sensitivity C-reactive protein and total antioxidant in renal transplant recipients with Renin-Angiotensin system polymorphisms. Transplantation Proceedings 2008;40(1):16-21. [MEDLINE: 18261537] (Pubitemid 351186634)
109. Ghorbanihaghjo A, Veisi P, Argani H, Aghaeishahsavari M, Noroozianavval M, Rashtchizadeh N, et al.Prevention of DNA damage in renal transplantation by losartan and enalapril: the role of renin-angiotensin system polymorphisms. Clinical & Experimental Nephrology 2008;12(1):65-73. [MEDLINE: 18175066]
110. Noroozianavval M, Argani H, Aghaeishahsavari M, Veisi P, Ghorbanihaghjo A, Rashtchizadeh N, et al.Renin-angiotensin system polymorphisms and hemoglobin level in renal allografts: a comparative study between losartan and enalapril. Transplantation Proceedings 2007;39(4):1018-1022 [MEDLINE: 17524880] (Pubitemid 46764818)
111. * Rashtchizadeh N, Aghaeishahsavari M, Argani H, Noroozianavval M, Veisi P, Ghorbanihaghjo A. Enalapril and losartan affect lipid peroxidation in renal transplant recipients with renin-angiotensin system polymorphisms. Clinical Biochemistry 2007;40(3-4):194-200. [MEDLINE: 17222813]
112. * Rump LC, Oberhauser V, Schwertfeger E, Speidel L, Zimmerhackl L, Kirste G, et al.Dihydropyridine calcium antagonists and renal function in hypertensive kidney transplant recipients. Journal of Hypertension 2000;18(8):1115-1119 [MEDLINE: 10954004]
113. * Santos AF, Keitel E, Bittar A, Neto JP, Alves MD, Schaefer PG, et al.Long term results of diltiazem use associated to cyclosporin in renal transplantation [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25-30; Miami (USA). 2002. [CENTRAL: CN-00416584]
114. * Schmidt A, Gruber U, Bohmig G, Koller E, Mayer G. The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA. Nephrology Dialysis Transplantation 2001;16(5):1034-1037 [MEDLINE: 11328912]
115. Schmidt A, Gruber U, Bohmig G, Koller E, Mayer G. The effect of ace inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with cyclosporin [abstract]. XVIII International Congress of the Transplantation Society; 2000 Aug 27-Sep 1; Rome (Italy). 2000. [CENTRAL: CN-00447624]
116. Schmidt A, Gruber U, Bohmig G, Koller E, Mayer G. The effect of ace inhibitor and angiotensin II receptor antagonist therapy on serumuric acid levels and potassiumhomestasis in hypertensive renal transplant recipients treated with cyclosporin A [abstract]. Journal of the American Society of Nephrology 1999;10(Program & Abstracts): 746A. [CENTRAL: CN-00644133]
117. * Sennesael J, Lamote J, Violet I, Tasse S, Verbeelen D. Comparison of perindopril and amlodipine in cyclosporine-treated renal allograft recipients. Hypertension 1995;26(3):436-444 [MEDLINE: 7649579]
118. Sennesael JJ, Lamote JG, Violet I, Tasse S, Verbeelen DL. Divergent effects of calcium channel and angiotensin converting enzyme blockade on glomerulotubular function in cyclosporine-treated renal allograft recipients. American Journal of Kidney Diseases 1996;27(5):701-708 [MEDLINE: 8629631] (Pubitemid 26135843)
119. * Sperschneider H, Wagner C, Korn A, Christians U. Effect of diltiazem on concentration of cyclosporin metabolites in Sandimmune and Neoral treated kidney transplant patients. Medizinische Klinik 1997;92(10):589-596 [MEDLINE: 9446006]
120. Wagner C, Sperschneider H, Korn A, Christians U. Influence of diltiazem on cyclosporine metabolites in renal graft recipients treated with Sandimmun and Neoral [abstract]. Journal of the American Society of Nephrology 1997;8(Program & Abstracts):707A. [CENTRAL: CN-00509549]
121. * Sperschneider H, Wagner C, Korn A, Christians U. Effect of diltiazem on concentration of cyclosporin metabolites in Sandimmune and Neoral treated kidney transplant patients. Medizinische Klinik 1997;92(10):589-596 [MEDLINE: 9446006]
122. Wagner C, Sperschneider H, Korn A, Christians U. Influence of diltiazem on cyclosporine metabolites in renal graft recipients treated with Sandimmun and Neoral [abstract]. Journal of the American Society of Nephrology 1997;8(Program & Abstracts):707A. [CENTRAL: CN-00509549]
123. Kawaguchi T, Takahara S, Tanaka T, Yazawa K, Hanafusa T, Shi Y, et al.Randomized prospective study of effects of ace inhibitors in renal transplantation: an analysis of safety and efficacy [abstract]. American Journal of Transplantation 2002;2(Suppl 3):382. [CENTRAL: CN-00415993]
124. * Takahara S, Moriyama T, Kokado Y, Hanafusa T, Yazawa K, Yi S, et al.Randomized prospective study of effects of benazepril in renal transplantation: An analysis of safety and efficacy. Clinical and Experimental Nephrology 2002;6(4):242-247 [CENTRAL: CN-00615857]
125. * Trivedi H, Lal SM. A prospective, randomized, open labeled crossover trial of fosinopril and theophylline in post renal transplant erythrocytosis. Renal Failure 2003;25(1):77-86. [MEDLINE: 12617335]
126. Tylicki L, Biedunkiewicz B, Chamienia A, Wojnarowski K, Zdrojewski Z, Aleksandrowicz E, et al.Renal allograft protection with angiotensin II type 1 receptor antagonists. American Journal of Transplantation 2007;7(1):243-248 [MEDLINE: 17227571] (Pubitemid 44952879)
127. * Tylicki L, Biedunkiewicz B, Chamienia A, Wojnarowski K, Zdrojewski Z, Rutkowski B. Randomized placebo-controlled study on the effects of losartan and carvedilol on albuminuria in renal transplant recipients. Transplantation 2006;81(1):52-56 [MEDLINE: 16421476]
128. Van den Dorpel MA, Zietse R, Ijzermans JN, Schalekamp MA, Weimar W. Effect of isradipine on cyclosporin A-related hypertension. Blood Pressure 1994;3(Suppl 1):50-53 [MEDLINE: 8205301] (Pubitemid 24088348)
129. * Van den Dorpel MA, Zietse R, Ijzermans JN, Wiemar W. Prophylactic isradipine treatment after kidney transplantation: a prospective double-blind placebo-controlled randomized trial. Transplantation International 1994;7(Suppl 1):S270-4. [MEDLINE: 11271223]
130. * van der Schaaf MR, Hene RJ, Floor M, Blankestijn PJ, Koomans HA. Hypertension after renal transplantation. Calcium channel or converting enzyme blockade?. Hypertension 1995;25(1):77-81. [MEDLINE: 7843758]
131. * van Riemsdijk IC, Mulder PG, de Fijter JW, Bruijn JA, van Hooff JP, Hoitsma AJ, et al.Addition of isradipine (Lomir) results in a better renal function after kidney transplantation: a double-blind, randomized, placebo-controlled, multi-center study. Transplantation 2000;70(1):122-126 [MEDLINE: 10919587]
132. * Vanrenterghem Y, Waer M, De Keyser P, Roels L, Michielsen P. Controlled trial of the protective effect of dihydroergotoxine (Hydergine) on cyclosporine-associated nephrotoxicity in renal graft recipients. Transplantation Proceedings 1988;20(3 Suppl 3):615-617 [MEDLINE: 3291296]
133. * Venkat-Raman G, Feehally J, Coates RA, Elliott HL, Griffin PJ, Olubodun JO, et al.Renal effects of amlodipine in normotensive renal transplant recipients. Nephrology Dialysis Transplantation 1999;14(2):384-388 [MEDLINE: 10069193]
134. Venkat-Raman G, Griffin P, Moore R, Goodship T. Effects of amlodipine on renal function and cyclosporine pharmacokinetics in normotensive renal transplant recipients [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid (Spain). 1995:381. [CENTRAL: CN-00509541]
135. Kunzendorf U, Walz G, Brockmoeller J, Neumayer HH, Jochimsen F, Roots I, et al.Effects of diltiazem upon metabolism and immunosuppressive action of cyclosporine in kidney graft recipients. Transplantation 1991;52(2):280-284 [MEDLINE: 1871801]
136. Neumayer HH, Kunzendorf U, Schreiber M. Protective effects of calcium antagonists in human renal transplantation. Kidney International - Supplement 1992;41:S87-93. [MEDLINE: 1377295]
137. Neumayer HH, Kunzendorf U, Schreiber M. Protective effects of diltiazem and the prostazycline analogue iloprost in human renal transplantation. Renal Failure 1992;14(3):289-296 [MEDLINE: 1380721]
138. Neumayer HH, Schreiber M, Wagner K. Prevention of delayed graft function by diltiazem and iloprost. Transplantation Proceedings 1989; Vol.21, issue 1 Pt 2:1221-1224 [MEDLINE: 2469225] (Pubitemid 19130809)
139. Neumayer HH, Schreiber M, Wagner K. Prevention of delayed graft function in cadaveric kidney transplants by the calcium antagonist diltiazem and the prostacyclin-analogue iloprost - outcome of a prospective randomized clinical trial. Progress in Clinical & Biological Research 1989; Vol.301:289-295 [MEDLINE: 2477852]
140. Neumayer HH, Schreiber M, Wagner K. Prevention of delayed graft function in cadaver kidney transplants by the calcium antagonist diltiazem and the prostacyclin analogue Iloprost: Outcome of a prospective randomised clinical trial [abstract]. Nephrology Dialysis Transplantation 1988; Vol.3, issue 4:572-573 [CENTRAL: CN-00260409]
141. Neumayer HH, Wagner K. Prevention of delayed graft function in cadaver kidney transplants by diltiazem: outcome of two prospective, randomized clinical trials. Journal of Cardiovascular Pharmacology 1987;10 Suppl 10:S170-7. [MEDLINE: 2455126] (Pubitemid 18113846)
142. Neumayer HH, Wagner K. Prevention of delayed graft function in cadaver kidney transplants by diltiazem [abstract]. Kidney International 1987;31(1):465. [CENTRAL: CN-00644227]
143. Wagner K, Albert S, Neumayer HH. Does the calcium antagonist diltiazem reduce cyclosporin-A nephrotoxicity? [abstract]. Nephrology Dialysis Transplantation 1986;1(2):141. [CENTRAL: CN-00260307]
144. Wagner K, Albrecht S, Neumayer HH. Prevention of posttransplant acute tubular necrosis by the calciumantagonist diltiazem: a prospective randomized study. American Journal of Nephrology 1987;7(4):287-291 [MEDLINE: 3318461] (Pubitemid 18014648)
145. * Wagner K, Albrecht S, Neumayer HH. Protective effect of the calcium antagonist diltiazem on acute kidney failure following kidney transplantation. The results of a prospective randomized study. Deutsche Medizinische Wochenschrift 1986;111(36):1363-1367 [MEDLINE: 3527645]
146. Wagner K, Neumayer HH. Clinical evidence for the protective role of the calcium antagonist diltiazem in acute renal failure (ARF) [abstract]. Clinical Transplantation 1987;Supplement:643. [CENTRAL: CN-00644225] (Pubitemid 17120860)
147. Wagner K, Neumayer HH. Effect of the calciumantagonist diltiazem on acute kidney failure following kidney transplantation. Results of 2 prospective randomized studies. Medizinische Klinik 1987;82(5):171-177 [MEDLINE: 3295505] (Pubitemid 17120860)
148. Wagner K, Neumayer HH. Prevention of delayed graft function in cadaver kidney transplants by diltiazem. Lancet 1985;2(8468):1355-1356 [MEDLINE: 2866402] (Pubitemid 16175435)
149. * Wahlberg J, Hanas E, Bergstrom C, Fellstrom B, Skarp-Orberg I, Frodin L. Diltiazem treatment with reduced dose of cyclosporine in renal transplant recipients. Transplantation Proceedings 1992;24(1):311-312 [MEDLINE: 1539291]
150. Wei C, Lin R, Fink JC, Klassen DK, Cangro CB, Drachenburg C, et al.Candesartan attenuates angiotensin II and TGF-beta tissue expression in renal biopsies of patients with chronic allograft nephropathy [abstract]. American Journal of Transplantation 2002;2(Suppl 3):150. [CENTRAL: CN-00416908]
151. Wei C, Lin R, Fink JC, Klassen DK, Cangro CB, Papadimitriou JC, et al.Candesartan reduces expression of angiotensin II and TGF-beta and increases DNA repair enzyme in human chronic allograft nephropathy [abstract]. American Journal of Transplantation 2003;3(Suppl 5):338. [CENTRAL: CN-00448312]
152. Wei C, Lin R, Fink JC, Klassen DK, Papadimitriou JC, Drachenburg CI, et al.Candesartan reduces DNA damage and increases DNA repair enzyme in renal biopsies of patients with chronic allograft nephropathy [abstract]. Journal of the American Society of Nephrology 2002;13(Program & Abstracts):24A. [CENTRAL: CN-00448313]
153. * Wei C, Lin R, Fink JC, Klassen DK, Papadimitriou JC, Drachenburg CI, et al.Reduced expression of angiotensin II and TGF-beta in renal biopsies of patients with chronic allograft nephropathy by candesartan [abstract]. Journal of the American Society of Nephrology 2002;13(Program & Abstracts):24A. [CENTRAL: CN-00448314]
154. Becker BN, Jacobson LM, Muehrer RJ, Djamali A, Hullett DA. Angiotensin receptor blockade has significant immunomodulatory effects in chronic allograft nephropathy [abstract]. Journal of the American Society of Nephrology 2003;14(Nov):418A. [CENTRAL: CN-00644292]
155. Becker BN, Jacobson LM, Muehrer RJ, Hullett DA. Chronic type 1 angiotensin II receptor blockade attenuates lymphocyte responsiveness in renal allograft recipients [abstract]. American Journal of Transplantation 2003; Vol.3, issue Suppl 5:309. [CENTRAL: CN-00444371]
156. * Weidanz JA, Jacobson LM, Muehrer RJ, Djamali A, Hullett DA, Sprague J, et al.ATR blockade reduces IFN-gamma production in lymphocytes in vivo and in vitro. Kidney International 2005;67(6):2134-2142 [MEDLINE: 15882256]
157. * Wilkie ME, Beer JC, Raftery MJ, Dawnay A, Barton C, Marsh FP. Effect of nifedipine on renal haemodynamics and urinary protein excretion in stable renal transplant recipients. Transplantation Proceedings 1993;25(1 Pt 1):612-615 [MEDLINE: 8438435]
158. * Wilkie ME, Beer JC, Raftery MJ, Dawnay A, Barton C, Marsh FP. Effect of nifedipine on renal haemodynamics and urinary protein excretion in stable renal transplant recipients. Transplantation Proceedings 1993;25(1 Pt 1):612-615 [MEDLINE: 8438435]
159. Wilkie ME, Beer JC, Evans C, Lord RH, Raftery MJ, Marsh FP. A prospective randomized double-blind placebo-controlled trial of oral nifedipine on early renal allograft function [abstract]. 12th International Congress of Nephrology; 1993 Jun 13-18; Jerusalem (Israel). 1993:156. [CENTRAL: CN-00644306]
160. Wilkie ME, Beer JC, Evans C, Lord RH, Raftery MJ, Marsh FP. Prospective trial of oral nifedipine on early renal allograft function [abstract]. Nephrology Dialysis Transplantation 1993; Vol.8, issue 9:1053-1054 [CENTRAL: CN-00260901]
161. * Wilkie ME, Beer JC, Evans SJ, Raftery MJ, Lord RH, Moore R, et al.A double-blind, randomized, placebo-controlled study of nifedipine on early renal allograft function. Nephrology Dialysis Transplantation 1994;9(7):800-804 [MEDLINE: 7970122]
162. * Yildiz A, Cine N, Akkaya V, Sahin S, Ismailoglu V, Turk S, et al.Comparison of the effects of enalapril and losartan on posttransplantation erythrocytosis in renal transplant recipients: prospective randomized study. Transplantation 2001;72(3):542-544 [MEDLINE: 11502994]
163. Yildiz A, Ismailoglu V, Erkoc R, Celik AV, Gorcin B, Sever MS, et al.The effect of enalapril and losartan in posttransplant erythrocytosis [abstract]. Nephrology Dialysis Transplantation 1999;14(9):A302. [CENTRAL: CN-00486536]
164. * Alexander JW, Metze TJ, McIntosh MJ, Goodman HR, First MR, Munda R, et al.The influence of immunomodulatory diets on transplant success and complications. Transplantation 2005;79(4):460-465 [MEDLINE: 15729173]
165. Almeshari K, Alshaibani K, Alfurayh O, Powe J, DeVol E. The antihypertensive and renal protective effects of amlodipine versus cilazapril in renal transplant recipients with hypertension [abstract]. Nephrology Dialysis Transplantation 2000;15(9):A70. [CENTRAL: CN-00460274]
166. Aros CA, Ardiles LG, Schneider HO, Flores CA, Alruiz PA, Jerez VR, et al.No gender-associated differences of cyclosporine pharmacokinetics in stable renal transplant patients treated with diltiazem. Transplantation Proceedings 2005;37(8):3364-3366 [MEDLINE: 16298597]
167. * Bailey RR. Open comparison of diuretic effects of piretanide and bumetanide in patients with stable renal transplants. New Zealand Medical Journal 1982;95(700):44-45 [MEDLINE: 7038567]
168. Bewick M. The use of Lasix post-operatively in clinical renal transplantation. Scottish Medical Journal 1974;19 Suppl 1:59-64. [MEDLINE: 4614443]
169. Borchhardt K, Haas M, Yilmaz N, Oberbauer R, Schmidt A, Barnas U, et al.Low dose ACE inhibition and glomerular permselectivity in renal transplant recipients [abstract]. Journal of the American Society of Nephrology 1997;8(Program & Abstracts):82A. [CENTRAL:CN-00444487]
170. Borchhardt K, Haas N, Yilmaz N, Oberbauer R, Schmidt A, Barnas U, et al.Low dose angiotensin converting enzyme inhibition and glomerular permselectivity in renal transplant recipients. Kidney International 1997;52(6):1622-1625 [MEDLINE: 9407509] (Pubitemid 28032067)
171. Bourbigot B, Legendre JM. Calcium blocker before cyclosporin A in kidney recipients [abstract]. Nephrology Dialysis Transplantation 1990;5(8):745. [CENTRAL: CN-00260579]
172. Branten AJ, Hilbrands LB, van Hamersvelt HW, Koene RA, Huysmans FT. Renal and systemic effects of atenolol and tertatolol in renal transplant recipients on cyclosporine A. Nephrology Dialysis Transplantation 1998;13(2):423-426 [MEDLINE: 9509456]
173. Calo L, Giacon B, Davis PA, Pagnin E, Piccin A, Riegler P, et al.Oxidative stress and TGFbeta in kidney-transplanted patients with cyclosporin-induced hypertension. Effect of carvedilol and nifedipine. Clinical Nephrology 2002;58(2):103-110 [MEDLINE: 12227681] (Pubitemid 34855089)
174. Carozzi S, Nasini MG, Pietrucci A, Nocera A, Fontana I, Valente U. Immunosuppressive effects of different calcium channel blockers in human kidney allografts. Transplantation Proceedings 1995;27(1):1054-1057 [MEDLINE: 7878801]
175. Cartier F, Merot ML. Effect of sustained release alprenolol in hypertension uncontrolled by chlorothiazide and dihydralazine. Study in double blind (author's transl). Semaine des Hopitaux 1978;54(25-28):855-857 [MEDLINE: 214866] (Pubitemid 9019540)
176. Castelao AM, Grino JM, Galceran JM, Andres E, Gil VS, Seron D, et al.Comparative randomized study of calcium channel blockers vs. angiotensin converting enzyme inhibitors in the treatment of hypertension under cyclosporine immunosuppression. Nefrologia 1993;13(Suppl 2):47-51. [CENTRAL: CN-00449897] (Pubitemid 23285986)
177. Martinez-Castelao A, Hueso M, Sanz V, Rejas J, Alsina J, Grinyo JM.Treatment of hypertension after renal transplantation: long-term efficacy of verapamil, enalapril, and doxazosin. Kidney International - Supplement 1998;68:S130-4. [MEDLINE: 9839297] (Pubitemid 28531789)
178. Christians U, Bleck JS, Lampen A, Bader A, Thiesemann C, Kliem V, et al.Are cytochrome P450 3A enzymes in the small intestine responsible for different cyclosporinemetabolite patterns in stable male and female renal allograft recipients after co-administration of diltiazem?. Transplantation Proceedings 1996;28(4):2159-2161 [MEDLINE: 8769186] (Pubitemid 26282407)
179. * Cieciura T, Senatorski G, Rell K, Baczkowska L, Paczek L, Gradowska L, et al.Influence of angiotensin-converting enzyme inhibitor treatment of the carotid artery intima-media complex in renal allograft recipients. Transplantation Proceedings 2000;32(6):1335-1336 [MEDLINE: 10995971]
180. Citterio F, Serino F, Pozzetto U, Fioravanti P, Caizzi P, Castagneto M. Verapamil improves Sandimmune immunosuppression, reducing acute rejection episodes. Transplantation Proceedings 1996;28(4):2174-2176 [MEDLINE: 8769192] (Pubitemid 26282413)
181. Colak T, Emirolu R, Karakayali H, Bilgin N, Haberal M. The comparison of angiotensin-converting enzyme inhibitors with calcium antagonists in renal transplant patients under cyclosporin treatment. Transplantation Proceedings 2001;33(5):2774-2775 [MEDLINE: 11498155] (Pubitemid 32725885)
182. Curtis JJ, Laskow DA, Jones PA, Julian BA, Gaston RS, Luke RG. Captopril-induced fall in glomerular filtration rate in cyclosporine-treated hypertensive patients. Journal of the American Society of Nephrology 1993;3(9):1570-1574 [MEDLINE: 8507812]
183. D'Amelio A, Bonucchi D, Patruno P, Ballestri M, Mastrangelo F. Treatment of post-transplant erythrocytosis: comparison of lisinopril and theophylline. Minerva Cardioangiologica 1997;45(11):567-572 [MEDLINE: 9549290] (Pubitemid 28123079)
184. Dawidson I, Rooth P, Fry WR, Sandor Z, Willms C, Coorpender L, et al.Prevention of acute cyclosporine-induced renal blood flow inhibition and improved immunosuppression with verapamil. Transplantation 1989;48(4):575-580 [MEDLINE: 2678635] (Pubitemid 19267471)
185. Dawidson I, Ar'Rajab A, Dickerman R, Husberg B, Klintmalm G, Lu C, et al.Perioperative albumin and verapamil improve early outcome after cadaver renal transplantation. Transplantation Proceedings 1994;26(6):3100-3101 [MEDLINE: 7998083]
186. Dominguez-Gil B, Ortiz M, Sierra MP, Munoz MA, Morales E, Andres A, et al.Losartan reduces massive proteinuria in kidney transplant patients: a pilot study. Transplantation Proceedings 2002;34(1):368-369 [MEDLINE: 11959331] (Pubitemid 34311715)
187. Donmez A, Karaaslan D, Sekerci S, Akpek E, Karakayali H, Arslan G. The effects of diltiazem and dopamine on early graft function in renal transplant recipients. Transplantation Proceedings 1999;31(8):3305-3306 [MEDLINE: 10616487]
188. Duggan KA, Macdonald GJ, Charlesworth JA, Pussell BA. Verapamil prevents post-transplant oliguric renal failure. Clinical Nephrology 1985;24(6):289-291 [MEDLINE: 3907910]
189. Erken U, Erken E, Tansu Z, Bayazit Y, Iik G, Turkyilmaz R. Beneficial effects of verapamil in renal transplantation. Transplantation Proceedings 1993;25(3):2187. [MEDLINE: 8516864] (Pubitemid 23194057)
190. Ferguson CJ, von Ruhland C, Shrestha B, Griffin PJ, Moore RH, Salaman JR. Enalapril and cyclosporin in renal transplant patients and rats. Transplantation Proceedings 1994;26(5):2600-2601 [MEDLINE: 7940808] (Pubitemid 24329246)
191. Hadjigavriel M, Kyriakides G. Efficacy and safety of losartan in renal transplant recipients. Transplantation Proceedings 1999;31(8):3300-3301 [MEDLINE: 10616484]
192. Hetzel GR, Schmitz M, Plum J, Voiculescu A, Grabensee B. Effects of candesartan on glomerular function in patients within the first year after renal transplantation [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon (Portugal). 2004:200-201 [CENTRAL: CN-00509447]
193. Hortal L, Fernandez A, Vega N, Rodriguez JC, Losada A, Lorenzo M, et al.Losartan versus ramipril in the treatment of postrenal transplant erythrocytosis. Transplantation Proceedings 1998;30(5):2127-2128 [MEDLINE: 9723415] (Pubitemid 28399451)
194. Inigo P, Torregrosa JV, Campistol JM, Oppenheimer F. Treatment with losartan in kidney transplant recipients with posttransplant erythrocytosis. Transplantation Proceedings 1999;31(6):2321. [MEDLINE: 10500598] (Pubitemid 29433931)
195. Ishikawa A, Kawabe K. Beneficial effect of losartan against proteinuria from the renal allograft. Transplantation Proceedings 2003;35(1):289-290 [MEDLINE: 12591404] (Pubitemid 36194611)
196. Ishikawa A, Ohta N, Kitamura T. Effect of losartan and temocapril on plasma plasminogen activator inhibitor-1 in cyclosporine-treated renal allograft recipients [abstract]. American Journal of Transplantation 2005;5(Suppl 11):320. [CENTRAL: CN-00644131]
197. Javid R, Ghahramani N, Malek-Hosseini SA, Behzadi S, Rais-Jalali GA. Management of posttransplant erythrocytosis with enalapril. Transplantation Proceedings 1999;31(8):3226. [MEDLINE: 10616453]
198. Kamper A, Nielsen AH. Uricosuric effect of losartan in renal transplanted patients. Transplantation Proceedings 2001;33(1-2):1201. [MEDLINE: 11267257] (Pubitemid 32237812)
199. Kamper A, Nielsen AH. Uricosuric effect of losartan in renal transplanted patients [abstract]. XVIII International Congress of the Transplantation Society; 2000 Aug 27-Sept 1; Rome (Italy). 2000. [CENTRAL: CN-00465804]
200. Kamper AL, Nielsen AH.Uricosuric effect of losartan in patients with renal transplants. Transplantation 2001;72(4):671-674 [MEDLINE: 11544429]
201. Kauffman HM, Adams MB, Hebert LA, Walczak PM. Platelet inhibitors in human renal homotransplantation: randomized comparison of aspirin versus dipyridamole. Transplantation Proceedings 1980;12(2):311-314 [MEDLINE: 6771905]
202. Kim W, Lee S, Kang SK, Yu HC, Cho BH, Park SK. Effects of angiotensin converting enzyme inhibitor and angiotensin II receptor antagonist therapy in hypertensive renal transplant recipients. Transplantation Proceedings 2002;34(8):3223-3224 [MEDLINE: 12493427] (Pubitemid 35463300)
203. Koller J, Wieser C, Kornberger R, Furtwangler W, Konigsrainer A, Margreiter R. Does systemic pretreatment with verapamil prevent acute tubular necrosis after renal transplantation?. Transplantation Proceedings 1988;20(5):905-906 [MEDLINE: 3055529] (Pubitemid 18261341)
204. Konstadinidou I, Boletis J. Long term effects of two ace inhibitors on erythropoiesis in renal transplantation [abstract]. Nephrology Dialysis Transplantation 1997;12(9):A227. [CENTRAL: CN-00261433]
205. Kunzendorf U, Walz G, Neumayer HH, Wagner K, Keller F, Offermann G. Effect of diltiazem on blood cyclosporin levels. Klinische Wochenschrift 1987;65(22):1101-1103 [MEDLINE: 3320488]
206. Kupin W, Venkat KK, Goggins M, Abouljoud M, Escobar F, Mozes M. Benefit of angiotensin II receptor blockade in the treatment of posttransplant polycythemia in renal transplant recipients. Transplantation Proceedings 1997;29(1-2):207-208 [MEDLINE: 9122965] (Pubitemid 27123377)
207. Lal SM, Trivedi HS, Ross G Jr. Long term effects of ACE inhibitors on the erythrocytosis in renal transplant recipients. International Journal of Artificial Organs 1995;18(1):13-16 [MEDLINE: 7607751]
208. Leeman M, Vereerstraeten P, Uytdenhoef M, Degaute JP. Systemic and renal hemodynamic responses to carvedilol andmetoprolol in hypertensive renal transplant patients. Journal of Cardiovascular Pharmacology 1993;22(5):706-710 [MEDLINE: 7506322] (Pubitemid 23315374)
209. Logan A. BENEDICT in the treatment of hypertension. Current Hypertension Reports 2005;7(2):121-123 [MEDLINE: 15748536]
210. MacKinnon M, Leenen FHH, Ruzicka M. Does ALLHAT change the management of hypertension in chronic kidney disease?. Current Hypertension Reports 2005;7(6):474-483 [MEDLINE: 16386205] (Pubitemid 43136944)
211. Madsen JK, Kornerup HJ, Pedersen EB. Effect of felodipine on renal haemodynamics and tubular sodium handling after single-dose cyclosporin infusion in renal transplant recipients treated with azathioprine and prednisolone. Scandinavian Journal of Clinical & Laboratory Investigation 1995;55(7):625-633 [MEDLINE: 8633187]
212. Madsen JK, Zachariae H, Pedersen EB. Beneficial effects of felodipine on renal hemodynamics, tubular sodium handling, and blood pressure in cyclosporine-treated dermatological patients [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid (Spain). 1995:36. [CENTRAL: CN-00550639]
213. Markell MS, Joseph N, Walters I, Friedman EA. Enalapril effectively treats diabetic and non-diabetic renal allograft recipients with posttransplant hypertension [abstract]. Kidney International 1990;37:401. [CENTRAL: CN-00644136]
214. McCune TR, Wombolt DG, Whelan TV, Thacker LR, Colonna JO. Vasodilatation vs. immunotherapy to prevent delayed graft function: delayed graft function as an indication of immune activation. International Immunopharmacology 2005;5(1):85-92. [MEDLINE: 15589464]
215. Mezzano S, Flores C, Ardiles L, Foradori A, Elberg A. Study of neoral kinetics in adult renal transplantation treated with diltiazem. Transplantation Proceedings 1998;30(5):1660-1662 [MEDLINE: 9723232] (Pubitemid 28399268)
216. Montanaro D, Groupuzzo M, Boscutti G, Risaliti A, Bresadola F, Mioni G. Long-term therapy for postrenal transplant erythrocytosis with ACE inhibitors: efficacy, safety and action mechanisms. Clinical Nephrology 2000;53(4 Suppl):47-51. [MEDLINE: 10809436] (Pubitemid 30204956)
217. Montanaro D, Gropuzzo M, Tulissi P, Vallone C, Boscutti G, Mioni R, et al.Renoprotective effect of early inhibition of the renin-angiotensin system in renal transplant recipients. Transplantation Proceedings 2005;37(2):991-993 [MEDLINE: 15848600] (Pubitemid 40590769)
218. Mourad G, Kharrat M, Turc-Baron C, Polensky U, Ribstein J. Comparative studies of renal hemodynamics and function in renal transplant recipients (RTR) treated by cyclosporine (CS) or tacrolimus (TC) [abstract]. Nephrology Dialysis Transplantation 1997;12(9):A205. [CENTRAL: CN-00509365]
219. Nanni G, Panocchia N, Tacchino R, Foco M, Piccioni E, Castagneto M. Increased incidence of infection in verapamil-treated kidney transplant recipients. Transplantation Proceedings 2000;32(3):551-553 [MEDLINE: 10812109] (Pubitemid 30254397)
220. Neumayer HH, Schreiber M, Wagner K. Prevention of delayed graft function by diltiazemand iloprost. Transplantation Proceedings 1989;21(1 Pt 2):1221-1224 [MEDLINE: 2469225] (Pubitemid 19130809)
221. Neumayer HH, Schreiber M, Wagner K. Prevention of delayed graft function in cadaveric kidney transplants by the calcium antagonist diltiazem and the prostacyclin-analogue iloprost - outcome of a prospective randomized clinical trial. Progress in Clinical & Biological Research 1989;301:289-295 [MEDLINE: 2477852]
222. Neumayer HH, Schreiber M, Wagner K. Prevention of delayed graft function in cadaver kidney transplants by the calcium antagonist diltiazemand the prostacyclin analogue Iloprost: Outcome of a prospective randomised clinical trial [abstract]. Nephrology Dialysis Transplantation 1988;3(4):572-573 [CENTRAL: CN-00260409]
223. Niyamathullah MM, Hariharan S, Jacob CK, Pandey AP, Gopalakrishnan G, Date A, et al.A controlled trial of dipyridamole as an immunomodulator in renal allograft recipients. Transplantation 1989;47(6):1071-1072 [MEDLINE: 2660346] (Pubitemid 19161852)
224. Noel C, Hazzan M, Coppin MC, Codaccioni MX, Pruvot FR, Labalette M, et al.A randomized controlled trial of pentoxifylline for the prevention of delayed graft function in cadaveric kidney graft. Clinical Transplantation 1997;11(3):169-173 [MEDLINE: 9193837] (Pubitemid 27230792)
225. Ogborn MR, Crocker JF, Belitsky P, MacDonald AS, Bitter-Suermann H, Digout SC. Cyclosporin A and hypertension in pediatric renal transplant recipients. Transplantation Proceedings 1989;21(1 Pt 2):1705-1706 [MEDLINE: 2652558] (Pubitemid 19130999)
226. Okuno Y, Mashimo T, TakashinaM, Hagihira S, Inagaki Y, Mori T, et al.Hemodynamic effects of amrinone combined with dopamine in patients undergoing living renal transplantation. Masui - Japanese Journal of Anesthesiology 1997;46(1):87-94. [MEDLINE: 9028089] (Pubitemid 27066009)
227. Opelz G, Wujciak T. Comparative analysis of kidney preservation methods. Collaborative Transplant Study. Transplantation Proceedings 1996;28(1):87-90. [MEDLINE: 8644351]
228. Oppenheimer F, Flores R, Cofan F, Campistol JM, Ochs J, Ricart MJ, et al.Treatment with angiotensin-converting enzyme inhibitors in renal transplantation with proteinuria. Transplantation Proceedings 1995;27(4):2235-2236 [MEDLINE: 7652787]
229. Orlic L, Sladoje-Martinovic B, Vlahovic A, Pavletic M, Racki S.Hypertension in patients with renal transplantation. Lijecnicki Vjesnik 2006;128(11-12):378-380 [MEDLINE: 17212201] (Pubitemid 44951141)
230. Paczek L, Pazik J, Gradowska L, Senatorski G, Lao M, Bartlomiejczyk I, et al.Intraglomerular cathepsin B and L activity in chronic kidney allograft rejection. Transplantation Proceedings 1995;27(1):932-933 [MEDLINE: 7879237]
231. Pisani F, Tisone G, Alciati E, Vennarecci G, Pieragostini E, Casciani CU. Role of ACE inhibitors in the treatment of erythrocytosis in patients with renal allograft. Transplantation Proceedings 1994;26(5):2602-2603 [MEDLINE: 7940809] (Pubitemid 24329247)
232. Ploeg RJ. Preliminary results of the European Multicenter Trial of UW and Euro-Collins solutions in kidney transplantation. The Study Group. Transplantation Proceedings 1990;22(5):2213-2215 [MEDLINE: 2219348]
233. Po C, Raja R, Morris M, Badosa F. Effect of varying doses of enalapril on post-transplant erythocytosis [abstract]. Journal of the American Society of Nephrology 1993;4(Program & Abstracts):956. [CENTRAL: CN-00485445]
234. Po C, Alvez L, Caldwell I, Raja R. Long term effects of calcium channel blockers on proteinuria in renal transplant patients on cyclosporine [abstract]. Journal of the American Society of Nephrology 1994;5(3):1030. [MEDLINE: CN-00644134]
235. Podobinska I, Sopniewska B, Mrowiec T, Korczak-Kowalska G, Wierzbicki P, Lis K, et al.Allogeneic sensitization alters T-cell reactivity to extracellular matrix proteins in prospective transplant recipients. Transplantation Proceedings 1995;27(1):494. [MEDLINE: 7879074]
236. Polyak MM, Arrington BO, Stubenbord WT, Kinkhabwala M. Prostaglandin E1 improves pulsatile preservation characteristics and early graft function in expanded criteria donor kidneys. ASAIO Journal 1998;44(5):M610-2. [MEDLINE: 9804507] (Pubitemid 28468911)
237. Porras I, Gonzalez-Posada JM, Losada M, Jordano A, Lorenzo V, Gonzalez-Miranda F, et al.A multivariate analysis of the risk factors for posttransplant renal failure: beneficial effect of a flush solution with mannitol. Transplantation Proceedings 1992;24(1):52-53 [MEDLINE: 1539340]
238. Puig JM, Lloveras J, Oliveras A, Costa A, Aubia J, Masramon J. Usefulness of diltiazem in reducing the incidence of acute tubular necrosis in Euro-Collins-preserved cadaveric renal grafts. Transplantation Proceedings 1991;23(5):2368-2369 [MEDLINE: 1926388]
239. Rhee SR, Park SK, Kang SK, Kim SH, Cho BH, Kim JH. Preventive effect of enalapril on erythrocytosis after renal transplantation. Transplantation Proceedings 1996;28(3):1555-1556 [MEDLINE: 8658783]
240. Richards KF, Belnap LP, Rees WV, Stevens LE. Mannitol reduces ATN in cadaveric allografts. Transplantation Proceedings 1989;21(1 Pt 2):1228-1229 [MEDLINE: 2496491]
241. Riggio R, Haschemeyer R, Cheigh J, Wong J, Tapia L, Sullivan J, et al.Does enalapril retard the progression of renal insufficiency in kidney transplant recipients? [abstract]. Journal of the American Society of Nephrology 1992;3(3):877. [CENTRAL: CN-00461597]
242. Rogan JW, Lyszkiewicz DA, Blowey D, Khattak S, Arbus GS, Koren G. A randomized prospective crossover trial of amlodipine in pediatric hypertension. Pediatric Nephrology 2000;14(12):1083-1087 [MEDLINE: 11045391] (Pubitemid 30757608)
243. Roy LF, East DS, Browning FM, Shaw D, Ogilvie RI, Cardella C, et al.Short-term effects of calcium antagonists on hemodynamics and cyclosporine pharmacokinetics in heart-transplant and kidney-transplant patients. Clinical Pharmacology & Therapeutics 1989;46(6):657-667 [MEDLINE: 2689045] (Pubitemid 20031848)
244. Ruggenenti P, Perico N, Mosconi L, Gaspari F, Benigni A, Amuchastegui CS, et al.Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. Kidney International 1993;43(3):706-711 [MEDLINE: 8455370] (Pubitemid 23071956)
245. Philipp T, Legendre C, Geiger H, Schmieder RE, Kiel G, Hubner R, et al.Study on the evaluation of candesartan cilexetil after renal transplantation (SECRET Study [abstract]. Kidney & Blood Pressure Research 2004;27(5-6):331-332 [CENTRAL: CN-00615858]
246. Shin GT, Cheigh JS, Riggio RR, Suthanthiran M, Stubenbord WT, Serur D, et al.Long-term beneficial effects of a nifedipine-supplemented immunosuppressive
247. Sobh MA, Shehab el-Din AB, Moustafa FE, el Far MA, Hussein ME, Gad HM, et al.A prospective randomized study of the protective effect of verapamil on ischemic renal injury in renal allotransplants. Transplantation Proceedings 1989;21(1 Pt 2):1230-1232 [MEDLINE: 2652404]
248. Sorensen SS, Skovbon H. Renal haemodynamic and tubular effects of felodipine in cyclosporin-treated renal transplant recipients [abstract]. Nephrology Dialysis Transplantation 1991;6(10):833. [CENTRAL: CN-00260665]
249. Spieker C, Zidek W, Barenbrock M, Sprakel B, Buchholz B, Rahn KH. Cardiovascular side effects after renal allograft rejection therapy with Orthoclone: prevention with nitrendipine. Journal of Cardiovascular Pharmacology 1991;18 Suppl 1:S79-S81. [MEDLINE: 1723464]
250. Spieker C, Barenbrock M, Hoeks AH, Zidek W, Rahn K. Effects of ace inhibitors and beta-blockers on arterial compliance [abstract]. Journal of the American Society of Nephrology 1993;4(Program & Abstracts): 540. [CENTRAL: CN-00485973]
251. Stempel CA, Arminio A, Bernal C, Rosito G, Weisinger J, Milanes CL. Use of angiotensin converting enzyme inhibitors in the post transplant period: prospective study [abstract]. Journal of the American Society of Nephrology 1993;4(Program & Abstracts):964. [CENTRAL: CN-00486011]
252. Suh BY, Suh JD, Kwun KB. Effect of captopril in the treatment of erythrocytosis after renal transplantation. Transplantation Proceedings 1996;28(3):1557-1558 [MEDLINE: 8658784]
253. Tenschert W, Harfmann P, Meyer-Moldenhauer WH, Arndt R, Klosterhalfen H. Kidney protective effect of diltiazem after renal transplantation with long cold ischemia time and triple-drug immunosuppression. Transplantation Proceedings 1991;23(1 Pt 2):1334-1335 [MEDLINE: 1989231]
254. Tsang WK, Tong KL, Chan HW. Blockade of angiotensin II AT 1 receptor reduces hematocrit in patients with posttransplant erythrocytosis. Transplantation Proceedings 1998;30(7):3072-3073 [MEDLINE: 9838354]
255. Venkat-Raman G, Feehally J, Elliott HL, Griffin P, Moore RJ, Olubodun JO, et al.Renal and haemodynamic effects of amlodipine and nifedipine in hypertensive renal transplant recipients. Nephrology Dialysis Transplantation 1998;13(10):2612-2616 [MEDLINE: 9794569] (Pubitemid 28445879)
256. Wlodarczyk Z, Oko A, Glyda M, Karczewski M, Idasiak-Piechocka I, Czekalski S. Effects of pentoxifylline treatment on delayed graft function in cadaveric kidney recipients. Transplantation Proceedings 2000;32(6):1382-1383 [MEDLINE: 10995988]
257. Zhang Y, Guan DL, Xia CQ, Han ZY, Xu JJ, Gao JZ, et al.Clinical study of Lipo PGE1-inhibiting platelet activation in acute rejection after kidney transplantation. Transplantation Proceedings 2005;37(10):4208-4210 [MEDLINE: 16387079] (Pubitemid 43015990)
258. Ibrahim HN. Angiotensin II Blockade for the prevention of cortical interstitial expansion and graft loss in kidney transplant recipients. ClinincalTrials.gov 2008. [: 00067990]
259. Knoll GA, Cantarovitch M, Cole E, Gill J, Gourishankar S, Holland D, et al.The Canadian ACE-inhibitor trial to improve renal outcomes and patient survival in kidney transplantation - study design. Nephrology Dialysis Transplantation 2008;23(1):354-358 [MEDLINE: 17848393] (Pubitemid 351767383)
260. Rustom R. Does lisinopril protect transplanted kidneys with chronic vascular rejection (CR) from progressive failure. Current Controlled Trials. [: ISRCTN76140647]
261. Weinstein AJ, Seliger SL, Weir MR, Daniel SJ. Angiotensin receptor blocker's effect on hemoglobin in renal transplant patients - an interim analysis of the specific management of anemia and hypertension in renal transplant recipients trial (SMAhRT) [abstract]. Journal of the American Society of Nephrology 2006;17(Abstracts):548A. [CENTRAL: CN-00602019]
262. Barama AA.Mechanisms and management of proteinuria in kidney transplant patients. Drugs 2008;68 Suppl 1:33-39 [MEDLINE: 18442299]
263. Baroletti SA, Gabardi S, Magee CC, Milford EL. Calcium channel blockers as the treatment of choice for hypertension in renal transplant recipients: fact or fiction. Pharmacotherapy 2003;23(6):788-801. [MEDLINE: 12820820] (Pubitemid 36629082)
264. Chhabra D, Grafals M, Skaro AI, Parker M, Gallon L. Impact of anemia after renal transplantation on patient and graft survival and on rate of acute rejection. Clinical Journal of The American Society of Nephrology: CJASN 2008;3(4):1168-1174 [MEDLINE: 18463170]
265. Thompson Healthcare. Ciclosporin DRUGDEX(R) Evaluation. Thompson Healthcare, (accessed November 2008).
266. Cruzado JM, Rico J, Grinyo JM. The renin angiotensin system-blockade in kidney transplantation: pros and cons. Transplant International 2008;21(4):304-313 [MEDLINE: 18266774] (Pubitemid 351348021)
267. Curtis JJ. Treatment of hypertension in renal allograft patients: does drug selection make a difference?. Kidney International - Supplement 1997;63:S75-7. [MEDLINE: 9407427]
268. DerSimonian R, Laird M. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-188 [MEDLINE: 3802833]
269. El-Agroudy AE, Bakr MA, Shehab El-Dein AB, Ghoneim MA. Death with functioning graft in living donor kidney transplantation: analysis of risk factors. American Journal of Nephrology 2003;23(3):186-193 [MEDLINE: 12711830]
270. Hariharan S, McBride MA, Cherikh WS, Tolleris CB, Bresnahan BA, Johnson CP. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney International 2002;62(1):311-318 [MEDLINE: 12081593] (Pubitemid 34754077)
271. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration. 2008. Available from www.cochranehandbook.org.
272. Hiremath S, Fergusson D, Doucette S, Mulay AV, Knoll GA. Renin angiotensin system blockade in kidney transplantation: A systematic review of the evidence. American Journal of Transplantation 2007;7(10):2350-2360 [MEDLINE: 17845569] (Pubitemid 47347851)
273. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al.Angiotensin-converting enzyme inhibitors and progression of non-diabetic renal disease: a meta-analysis of patient-level data. Annals of Internal Medicine 2001;135(2):73-87. [MEDLINE: 11453706] (Pubitemid 32661190)
274. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. American Journal of Kidney Diseases 2004;43(5 Suppl 1):1-290. [MEDLINE: 15114537]
275. Kasiske BL, Guijarro C, Massy ZA, Wiederkehr MR, Ma JZ.Cardiovascular disease after renal transplantation. Journal of the American Society of Nephrology 1996;7(1):158-165 [MEDLINE: 8808124]
276. Kasiske B, Chakkera HA, Roel J.Explained and unexplained ischemic heart disease risk after renal transplantation. Journal of the American Society of Nephrology 2000;11(9):1735-1743 [MEDLINE: 10966499] (Pubitemid 30679723)
277. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. American Journal of Transplantation 2003;3(2):178-185 [MEDLINE: 12603213] (Pubitemid 36323115)
278. Kendrick E. Cardiovascular disease and the renal transplant recipient. American Journal of Kidney Diseases 2001;38(6 Suppl 6):S36-43. [MEDLINE: 11729004] (Pubitemid 34184671)
279. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease. Annals of Internal Medicine 2008;148(1):30-48. [MEDLINE: 17984482] (Pubitemid 351688350)
280. Lenihan CR, O'Kelly P, Mohan P, Little D, Walshe JJ, Kieran NE, et al.MDRD-estimated GFR at one year post-renal transplant is a predictor of long-term graft function. Renal Failure 2008;30(4):345-352 [MEDLINE: 18569905] (Pubitemid 351868679)
281. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al.Renal outcomes with telmisartan, ramipril or both, in people at high vascular risk (the ONTARGET study): amulticentre, randomised, double-blind controlled trial. Lancet 2008;372(9638):547-553 [MEDLINE: 18707986]
282. Nicholls K. The CARI guidelines. Prevention of progression of kidney disease. ACE inhibitor treatment in diabetic nephropathy. Nephrology 2006;11(Suppl 1):S79-91. [MEDLINE: 16684077]
283. Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Kidney International 1998;53(1):217-222 [MEDLINE: 9453022] (Pubitemid 28066925)
284. Opelz G, Zeier M, Laux G, Morath C, Dohler B. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report. Journal of the American Society of Nephrology 2006;17(11):3257-3262 [MEDLINE: 17035607] (Pubitemid 44707788)
285. Page RL 2nd, Miller GG, Lindenfeld J. Drug therapy in the heart transplant recipient: part IV: drug-drug interactions. Circulation 2005;111(2):230-239 [MEDLINE: 15657387]
286. Strippoli GF, Bonifati C, Craig ME, Navaneethan SD, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database of Systematic Reviews 2006, Issue 4. [DOI: 10.1002/14651858.CD006257] (Pubitemid 46841144)
287. Taal MW, Tomson C. UK Renal Association Clinical Practice Guidelines. Module 1: Chronic Kidney Disease. http: //www.renal.org/pages/media/download- gallery/CKDglinesreformatjan08.pdf (accessed May 2009).
288. Thompson Healthcare. Tacrolimus DRUGDEX(R) Evaluation. Thompson Healthcare, (accessed November 2008).
289. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted?. Statistics in Medicine 2002;21(11):1559-1573 [MEDLINE: 12111920]
290. Cross NB, Webster AC, Masson P, O'Connell PJ, Craig JC. Antihypertensives for kidney transplant recipients: systematic review and meta-analysis of randomised controlled trials. Transplantation 2009;Jul(in press).
291. Risler T, Braun N, Bachmann F. Antihypertensive treatment for kidney transplant recipients. Cochrane Database of Systematic Reviews 2002, Issue 2. [DOI: 10.1002/14651858.CD003598]